MHRAsafety guidance72% confidence
Guidance: Submit changes to labels and Patient Information Leaflets as a self-certification
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to UCB Biopharma.
Regulatory Analysis
Guidance for submitting changes to labels and Patient Information Leaflets (PILs) as a self-certification.
Supporting Context
- Therapeutic area
- Neurology · SLC6A1-NDD
- Sub-indication
- General
Related signal: UCB Biopharma initiates SLC6A1-NDD natural history study to inform future clinical trials